
DSA provides a non-invasive device for rapid COVID-19 screening. Its BreathPass handheld device detects volatile organic compounds to indicate infection. The system uses nano-sensor arrays and AI-powered analysis to deliver presumptive results in real time. Targeted at healthcare and enterprise screening contexts, it integrates into clinical and workplace workflows. DSA is expanding non-invasive screening capabilities and exploring broader respiratory disease indicators.

DSA provides a non-invasive device for rapid COVID-19 screening. Its BreathPass handheld device detects volatile organic compounds to indicate infection. The system uses nano-sensor arrays and AI-powered analysis to deliver presumptive results in real time. Targeted at healthcare and enterprise screening contexts, it integrates into clinical and workplace workflows. DSA is expanding non-invasive screening capabilities and exploring broader respiratory disease indicators.